U.S. News
Novo Nordisk Debuts Wegovy Weight-Loss Pill Option
Clear Facts
- Novo Nordisk is launching its once-daily Wegovy pill for weight loss in the U.S. at $149 per month for self-pay patients, with 1.5 mg and 4 mg doses available.
- The pill, which offers an alternative to injectables for those who dislike needles, will also be available in 9 mg and 25 mg doses for $299 monthly, and the 4 mg dose will rise to $199 starting April 15.
- Novo Nordisk offers starter doses at $149 per month under a deal that includes availability for Medicare and Medicaid enrollees, as well as cash payers using the new TrumpRx site.
The U.S. Food and Drug Administration approved Novo Nordisk’s Wegovy pill last month, boosting the company’s position in the competitive weight-loss market. The once-daily oral option aims to attract consumers who want easier alternatives to injections.
“The treatment offers more flexibility and an alternative for those who dislike needles used in injectable medication.”
The Wegovy pill contains semaglutide, the same compound as in Novo Nordisk’s injectable treatments Wegovy and Ozempic, and the diabetes pill Rybelsus. Shares of Novo Nordisk rose on the announcement, signaling market optimism.
The company says supplies are sufficient to meet anticipated demand, after earlier shortages following its injectable’s launch. U.S. pharmacies like CVS and Costco, along with telehealth providers, will offer the treatment to consumers seeking weight-loss solutions.
Let us know what you think, please share your thoughts in the comments below.
